Скачать с ютуб Navigating A New Path to Nav1.7 for Pain Presented by Rajesh Khanna, Ph.D. | AnaBios Presentation в хорошем качестве

Navigating A New Path to Nav1.7 for Pain Presented by Rajesh Khanna, Ph.D. | AnaBios Presentation

Pain remains a global health crisis. Despite extensive efforts by big pharmaceutical companies and academic labs worldwide, only opioids (new formulations of enhanced potency) have emerged clinically in the last few decades. While efficient for acute pain treatment, there is unanimous consensus that opioids are not recommended for treatment of long-term chronic pain. New, non-opioid, drugs are urgently needed. The NaV1.7 sodium channel is a prized target for pain therapeutics since mutations in the human gene, SCN9A, have been reported to produce both too much pain – due to gain-of-function mutations – or no pain – due to loss-of-function mutations. But despite these genetic links, development of NaV1.7 inhibitors has been unsuccessful due to reported lack of selectivity, insufficient channel blockade, and failure to engage NaV1.7-dependent endogenous opioid signaling. In this 2023 Translational Research Conference presentation, Dr. Rajesh Khanna, Director of the New York University Pain Research Center, synthesizes the history and discovery of this validated target, discusses the identification of NaV1.7 as a pharmacogenomic target and illustrates the allosteric and gene therapy-based therapeutic potential of NaV1.7. He also discusses how use of non-human primate-based assays may offer a hope for the future therapeutics targeting this channel. To learn more about AnaBios and our human tissue and functional assay services, please visit http://www.anabios.com.